Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

NCT07013851 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Cáncer de Ovario as lead sponsor.

NCT NCT07013851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07013851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Lead sponsor
Grupo Español de Investigación en Cáncer de Ovario
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
October 1, 2029
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mmrd/msi-h stage ii-iii endometrial cancer